会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Disubstituted piperidine derivatives as neuroprotective agents
    • 二取代哌啶衍生物作为神经保护剂
    • US5968955A
    • 1999-10-19
    • US43906
    • 1998-03-31
    • Sergio ManteganiTiziano BandieraManuela VillaMario VarasiCarmela Speciale
    • Sergio ManteganiTiziano BandieraManuela VillaMario VarasiCarmela Speciale
    • A61K31/00A61K31/445A61K31/4465A61K31/4523A61K31/454A61P25/00A61P25/04C07D413/06
    • C07D413/06
    • A Disubstituted piperidine compounds of formula (I), wherein R.sub.1 is hydrogen; bromo; chloro; a linear or branched C.sub.1 -C.sub.5 alkyl group; a linear or branched C.sub.1 -C.sub.5 alkoxy group; or an optionally substituted phenyl group; R.sub.2 is hydrogen, a linear or branched C.sub.1 -C.sub.5 alkyl group or an optionally substituted phenyl group; X is CH.sub.2, C.dbd.O, CHOH or C.dbd.NOH; R.sub.3 is hydrogen or a linear or branched C.sub.1 -C.sub.5 alkyl group; Y is a (CH.sub.2).sub.n group in which n is an integer from 0 to 4, CHOH, C.dbd.O or CH-A wherein A is an optionally substituted phenyl group; A is an optionally substituted phenyl group; W is hydrogen or hydroxy; stereoisomers thereof and their pharmaceutically acceptable salts. The compounds possess selective neuroprotective activity and are useful in the treatment of an acute or a degenerative CNS disease. A process is described for preparing the compounds and pharmaceutical compositions containing them.
    • PCT No.PCT / EP95 / 04075第 371日期1998年3月31日 102(e)1998年3月31日PCT PCT 1996年9月16日PCT公布。 公开号WO97 / 13769 日期1997年4月17日A式(I)的二取代哌啶化合物,其中R 1是氢; 溴 氯 直链或支链C 1 -C 5烷基; 直链或支链C 1 -C 5烷氧基; 或任选取代的苯基; R2是氢,直链或支链C1-C5烷基或任意取代的苯基; X是CH 2,C = O,CHOH或C = NOH; R3是氢或直链或支链C1-C5烷基; Y为(CH 2)n基团,其中n为0至4的整数,CHOH,C = O或CH-A,其中A为任选取代的苯基; A是任选取代的苯基; W是氢或羟基; 其立体异构体及其药学上可接受的盐。 该化合物具有选择性神经保护活性,可用于治疗急性或退行性CNS疾病。 描述了制备含有它们的化合物和药物组合物的方法。
    • 3. 发明授权
    • 5-(3-Phenyl-3-oxo-propyl)-1H-tetrazole derivatives
    • 5-(3-苯基-3-氧代 - 丙基)-1H-四唑衍生物
    • US6133302A
    • 2000-10-17
    • US446895
    • 1999-12-30
    • Paolo PevarelloAntonio GiordaniManuela VillaCarmela SpecialeMario Varasi
    • Paolo PevarelloAntonio GiordaniManuela VillaCarmela SpecialeMario Varasi
    • A61K31/41A61P25/00A61P43/00C07D257/04
    • C07D257/04
    • 5-(3-phenyl-3-oxo-propyl)-1H-tetrazole derivatives of formula (I) wherein each of R and R.sub.1, being the same or different, is hydrogen, halogen, hydroxy, trifluoromethyl, cyano, nitro, phenyl, benzyl, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkylthio, SOR.sub.4 or SO.sub.2 R.sub.4 wherein R.sub.4 is C.sub.1 -C.sub.6 alkyl, --N(R.sub.5 R.sub.6) in which each of R.sub.5 and R.sub.6 is, independently, hydrogen, C.sub.1 -C.sub.6 alkyl, formyl or C.sub.2 -C.sub.6 acyl; R.sub.2 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, benzyl, phenyl; R.sub.3 is hydrogen, hydroxy, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, benzyl, phenyl or a group --N(R.sub.7 R.sub.8) in which each of R.sub.7 and R.sub.8 is, independently, hydrogen, C.sub.1 -C.sub.4 alkyl, benzyl, phenyl, or one of R.sub.7 and R.sub.8 is hydrogen and the other is COR.sub.9 wherein R.sub.9 is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, phenyl or a group --N(R.sub.10 R.sub.11) in which R.sub.10 and R.sub.11 are, each independently, hydrogen or C.sub.1 -C.sub.4 alkyl or, taken together, R.sub.2 and R.sub.3 form a carbocyclic C.sub.3 -C.sub.6 ring; and pharmaceutically acceptable salts thereof have kynurenine-3-hydroxylase enzyme inhibitory activity. ##STR1##
    • PCT No.PCT / EP98 / 04032 Sec。 371 1999年12月30日第 102(e)1999年12月30日PCT PCT。1998年6月25日PCT公布。 公开号WO99 /​​ 02506 日本1月21日,19995-(3-苯基-3-氧代 - 丙基)-1H-四唑衍生物,其中R和R 1相同或不同,为氢,卤素,羟基,三氟甲基, 氰基,硝基,苯基,苄基,C1-C6烷基,C1-C6烷氧基,C1-C6烷硫基,SOR4或SO2R4,其中R4是C1-C6烷基,-N(R5R6),其中R5和R6各自独立地为 氢,C 1 -C 6烷基,甲酰基或C 2 -C 6酰基; R2是氢,C1-C6烷基,C1-C6烷氧基,苄基,苯基; R3是氢,羟基,C1-C6烷基,C1-C6烷氧基,苄基,苯基或基团-N(R7R8),其中R7和R8各自独立地是氢,C1-C4烷基,苄基,苯基或 R 7和R 8中的一个是氢,另一个是COR 9,其中R 9是氢,C 1 -C 4烷基,C 1 -C 4烷氧基,苯基或基团-N(R 10 R 11),其中R 10和R 11各自独立地是氢或C1- C4烷基或一起为R2和R3形成碳环C 3 -C 6环; 及其药学上可接受的盐具有犬尿氨酸-3-羟化酶抑制活性。
    • 4. 发明授权
    • Substituted kynurenines and process for their preparation
    • 替代的犬尿苷及其制备方法
    • US5786508A
    • 1998-07-28
    • US411656
    • 1995-04-06
    • Robert SchwarczMario VarasiArturo Della TorreCarmela SpecialeAlberto Bianchetti
    • Robert SchwarczMario VarasiArturo Della TorreCarmela SpecialeAlberto Bianchetti
    • C07C229/36A61K31/195C07C239/36
    • C07C229/36C07C2101/14
    • The present invention relates to the use in the treatment of cognitive disorders associated with the aging processes of the brain and perinatal brain disorders of compounds which act as inhibitors of the enzyme kynurenine aminotransferase (KAT). The present invention also provides, as novel compounds, a selected class of KAT inhibitors which are the compounds of formula (IA) ##STR1## wherein R is halogen, C.sub.1 -C.sub.6 alkyl, C.sub.5 -C.sub.7 cycloalkyl, phenyl-C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.6 -C.sub.10 aryloxy, phenyl-C.sub.1 -C.sub.4 alkoxy or trifluoromethyl, and R.sub.1 is hydroxy, C.sub.1 -C.sub.6 alkoxy, amino, mono-C.sub.1 -C.sub.6 alkylamino, di-C.sub.1 -C.sub.6 alkylamino, hydroxylamino, C.sub.1 -C.sub.4 alkoxyamino or benzyloxyamino, with the provisos that: (i) when R.sub.1 is hydroxy and, at the same time, R is halogen, then this halogen is not fluorine; and (ii) when R.sub.1 is hydroxy and, at the same time, R is C.sub.1 -C.sub.6 alkyl, then this C.sub.1 -C.sub.6 alkyl is not methyl, either as a single isomer or as a mixture of isomers, and the pharmaceutically acceptable salts thereof.
    • PCT No.PCT / US94 / 07804 Sec。 371日期:1995年4月6日 102(e)日期1995年4月6日PCT 1994年7月15日PCT公布。 公开号WO95 / 04714 日期1995年2月16日本发明涉及用作治疗与作为犬尿氨酸转氨酶(KAT)酶抑制剂的化合物的脑老化过程和围产期脑疾病相关的认知障碍的用途。 本发明还提供作为新化合物的选择类别的作为式(IA)化合物的KAT抑制剂,其中R是卤素,C 1 -C 6烷基,C 5 -C 7环烷基,苯基-C 1 -C 4烷基, C 1 -C 6烷氧基,C 6 -C 10芳氧基,苯基-C 1 -C 4烷氧基或三氟甲基,R 1是羟基,C 1 -C 6烷氧基,氨基,单-C 1 -C 6烷基氨基,二-C 1 -C 6烷基氨基,羟基氨基,C 1 -C 4 烷氧基氨基或苄氧基氨基,条件是:(ⅰ)当R 1为羟基,同时R为卤素时,该卤素不为氟; 和(ii)当R 1是羟基,并且同时R是C 1 -C 6烷基时,则该C 1 -C 6烷基不是甲基,作为单一异构体或作为异构体的混合物,以及其药学上可接受的盐 。